Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is designed with technology that enables longer dosing intervals and the company is proceeding with development of this engineered peptide as a monotherapy and as part of a drug combination.
The post Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med appeared first on MedCity News.
